Interaction Guide · Research summary

Can I take Withania Somnifera with Estazolam?

Review Withania Somnifera with Estazolam: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Review ashwagandha before adding it to estazolam. Some preparations can cause drowsiness, and official guidance notes possible sedative interactions.

What this answer covers

Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products.

Supplement or preparation
Withania somnifera
Medication ingredient
estazolam

Why product review is reasonable

NCCIH notes that ashwagandha can cause drowsiness and may interact with sedatives. This supports reviewing the specific extract alongside the medicine’s own alertness effects.

What the root-extract trial can tell us

A sleep trial reported improvement with its ashwagandha root extract, but no significant between-group difference in morning alertness. People taking regular medicines were excluded, so it did not test this combination.

Keep root and leaf products distinct

Bring the plant part, extract strength, dose and full blend label to the pharmacist. Neither the trial nor guidance provides a proven protective spacing interval.

Watch for impaired alertness

Estazolam can affect alertness and coordination. Avoid driving if affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about alcohol, opioids and all other sedating products.

Evidence and practical considerations

Side effects & toxicity

Conditional alertness precaution is supported, without claiming every preparation causes sedation or a proven exact combination effect.

Exact scope
Oral Withania somnifera preparations; the cited sleep trial used a specific root extract, not arbitrary leaf or mixed products. with Exact oral estazolam tablets. Human liver microsomes identify CYP3A metabolism; label predicts effects of strong inhibitors/inducers but explicitly lacks in vivo studies with those CYP3A classes. Parent drug contributes most hypnotic effect; limited metabolites are not assumed equivalent.
Medication form and route
oral
Timing or duration
Source-specific single-dose, repeated-dose and observational exposures distinguished.

What remains uncertain

  • Root-extract sleep trial excluded regular medication users and found no between-group morning-alertness difference; no exact co-use study.

Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral estazolam.

Can impair alertness and coordination; other CNS depressants can increase impairment. Opioid combinations have a specific respiratory-depression warning. Dependence and withdrawal require supervised changes. Human liver microsomes identify CYP3A metabolism; label predicts effects of strong inhibitors/inducers but explicitly lacks in vivo studies with those CYP3A classes. Parent drug contributes most hypnotic effect; limited metabolites are not assumed equivalent.

How this applies: Exact IN and labeled oral formulation; route, salt and metabolite distinctions retained.

No quantified risk for every herb or universal protective spacing interval. Opioid-specific evidence does not prove equal botanical respiratory risk.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Some preparations can cause drowsiness; possible interaction with sedatives. Products and studied preparations vary.

How this applies: Preparation-specific context; not a directly measured estazolam interaction.

No direct estazolam study; short-term safety observations do not establish long-term safety.

Source 3: randomized placebo-controlled trial

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 60 adults enrolled with insomnia and anxiety.

Some sleep outcomes improved; no adverse events were reported. Morning alertness did not differ significantly between groups at ten weeks.

How this applies: Original named medication and preparation only; indirect evidence for estazolam. Comparator arms are not coadministration.

Regular medication users and people with restless legs syndrome or other sleep disorders were excluded. Exploratory study; internal reporting inconsistencies in analysis counts. Cannot extend to estazolam-treated patients or leaf preparations.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Current exact available claims adjudicated using original captures and explicit identity and comparator limits.
Research summary published

Article revision: d20d0f6e8f4b3bf3

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.